Preparation and in-vitro release rate of fentanyl-cyclodextrin complexes for prolonged action in epidural analgesia

International Journal of Pharmaceutics

Volumn 265, Issue 1-2, 2003, Pages 13-26

  Holvoet, C ^a   Plaizier Vercammen, J ^a   Vander Heyden, Y ^a   Gabriels M ^a   Camu, F ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Cyclodextrins; Epidural use; Fentanyl; In vitro release studies in static and dynamic conditions; Inclusion complexation; Prolonged action formulation

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANALGESIC AGENT; ANESTHETIC AGENT; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CYCLODEXTRIN DERIVATIVE; FENTANYL; MALTOSYL BETA CYCLODEXTRIN; UNCLASSIFIED DRUG;

ANALGESIA; ARTICLE; ARTIFICIAL MEMBRANE; COMPLEX FORMATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; EPIDURAL ANESTHESIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PH MEASUREMENT; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 0141533131     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00368-5     Document Type: Article

References (32)

1. Barthélémy C., Lefebvre C., Guyot-Hermann A.-M. Concept and study of a new membrane for simulating passive absorption. Farmaco Prat. 41:1986;363-376.
2. Bernards C.M. Effect of (hydroxypropyl)-β-cyclodextrin on flux of morphine, fentanyl, sulfentanyl, and alfentanyl through the spinal meninges of monkey. J. Pharm. Sci. 83:1994;620-622.
3. Bernards C.M., Luger T., Malmberg A., Hill H., Yakhs T. Liposome encapsulation prolongs alfentanil spinal analgesia and alters systemic redistribution in the rat. Anesthesiology. 77:1992;529-535.
4. Bettini R., Santi P., Catellani P.L., Massimo G., Berlotti A., Barthélémy C., Guyot-Hermann A.-M., Trublin F., Colombo P. Permeation of piroxicam and piroxicam-β-cyclodextrin through artifical membranes. Eur. J. Pharm. Bioparm. 36:1992;203-208.
5. Brewster, M., 1991. In: Duchêne, D. (Ed.), New Trends in Cyclodextrins and Derivatives. Editions de Santé, Paris, pp. 31-350.
6. Carpenter T., Pettifor J., Russell R., Pitha J., Mobarhan S., Ossip M., Wainer S., Anast C. Severe hypervitaminosis A in siblings: evidence of variable tolerance to retinol intake. J. Pediatr. 111:1987;507-512.
7. 14C -labelled hydroxypropyl-β-cyclodextrin in rats following oral administration. In: Duchêne, D. (Ed.), Minutes of 5th International Symposium on Cyclodextrins. Editions de Santé, Paris, pp. 507-513.
8. Gupta S.K., Southam M., Sathyan G., Klausner M. Effect of current density on pharmacokinetics following continuous or intermittent input from a fentanyl electrotransport system. J. Pharm. Sci. 87:1998;976-981.
9. Higuchi T., Connors K. Phase-solubility techniques. Adv. Anal. Chem. Instrum. 4:1965;117-212.
10. Irie T., Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 86:1997;147-162.
11. Jang J., Yaksh T., Hill H. Use of 2-hydroxypropyl-β-cyclodextrin as an intrathecal drug vehicle with opioids. J. Pharmacol. Exp. Ther. 261:1992;592-600.
12. Klepper D., Sherril D.L., Boetger C.L., Bromage P.R. Analgesic and respiratory effects of extradural sufentanil in volunteers and the influence of adrenaline as an adjuvant. Br. J. Anaesth. 59:1987;1147-1156.
13. Lambropoulos J., Spanos G.A., Lazaridis N.V., Ingallinera T.S., Rodriguez V.K. Development and validation of an HPLC assay for fentanyl and releated substances in fentanyl citrate injection. J. Pharm. Biomed. Anal. 20:1999;705-716.
14. Lambropoulos J., Spanos G.A., Lazaridis N.V. Development and validation of an HPLC assay for fentanyl, alfentanil and sufentanil in swab samples. J. Pharm. Biomed. Anal. 23:2000;421-428.
15. Langerman L., Eliahu G., Benita S. Prolongation of the pharmacologic effect of intrathecal meperidine by the use of a lipid solution of it. Anesth. Analg. 72:1991;635-638.
16. Loftsson T., Siguroardottir A.M. The effect of polyvinylpyrrolidone and hydroxypropyl methyl cellulose on HP-β-CD complexation of hydrocortisone and its permeability through hairless mouse skin. Eur. J. Pharm. Sci. 2:1994;297-301.
17. Loftsson T., Frioriksdottir H., Thorisdottir S., Stefansson E. The effect of hydroxypropyl methylcellulose on the release of dexamethasone from aqueous 2-hydoxypropyl-β-cyclodextrin formulations. Int. J. Pharm. 104:1994a;181-184.
18. Loftsson T., Frioriksdottir H., Thorisdottir S., Stefansson E., Siguroardottir A.M., Guomundsson O., Sigthorsson T. 2-Hydroxypropyl-β -cyclodextrin in topical carbonic anhydrase inhibitor formulations. Eur. J. Pharm. Sci. 1:1994b;175-180.
19. Martin, A., 1993. Physical Pharmacy, 4th ed. Williams & Wilkins, Philadelphia, pp. 407-408.
20. McCandless R., Yalkowsky S. Effect of hydroxypropyl-beta-cyclodextrin and pH on the solubility of levemopamil HCl. J. Pharm. Sci. 12:1998;1639-1642.
21. Meert T.F., Melis W. Interactions between epidurally and intrathecally administered sufentanil and bupivacaine in hydroxypropyl-β-cyclodextrin in the rat. Acta Anaesth. Belg. 43:1992;79-89.
22. 2-adrenoreceptor agonist, the volume of injection, and the global pain state of the animal on the activity of epidural sufentanil. Acta Anaesth. Belg. 40:1989;247-261.
23. Meert T.F., Mesens J., Verheyen P., Noorduin H. Hydroxypropyl-β -cyclodextrin can modulate the activity of spinally administerd sufentanil. Eur. J. Anaesth. 9:1992;399-409.
24. Nakano M., Juni K., Arita T. Controlled drug permeation: I. Controlled release of butamben through silicone membrane by complexation. J. Pharm. Sci. 65:1976;709-712.
25. Pitha J. Amorphous water-soluble derivatives of cyclodextrins: nontoxic dissolution enhancing excipients. J. Pharm. Sci. 74:1985;987-990.
26. Szejtli, J., 1987. The metabolism, toxicity and biological effects of cyclodextrins. In: Duchêne, D. (Ed.), Cyclodextrins and their Industrial Uses. Editions de Santé, Paris, pp. 175-257.
27. Ritschel, W., 1986. Handbook of Basic Pharmacokinetics, 3rd ed. Drug Intelligence Publications, Hamilton Inc., Hamilton, IL, USA, pp. 270-272.
28. van Lersberghe C., Camu F., de Keersmaecker E., Sacré S. Continuous administration of fentanyl for postoperative pain: a comparison of the epidural, intravenous and transdermal routes. J. Clin. Anesth. 6:1994;308-314.
29. Vandewoude K., Vogelaers D., Decruyenaere J., Jaqmin P., De Beule K., Van Peer A., Woestenborghs R., Groen K., Colardyn F. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob. Agents Chemother. 41:1997;2714-2718.
30. Vercauteren, M., Moens, F., Hanegreefs, G., 1987. Modification of analgesic quality and side effects of epidural sufentanil. In: Scherpereel, P., Meynadier, J., Blonds, S. (Eds.), The Pain Clinic II. VNU Science Press, The Netherlands, pp. 299-301.
31. Vercauteren M., Meert T.F., D'Hooghe A., Boersma F., Melis W. Spinal sufentanil in rats. Part III: Effect of diluent volume on epidural sufentanil. Acta Anaesth. Scand. 36:1992;305-308.
32. Vikmon, M., 1981. Rapid and simple spectrophotometric method for determination of micro-amounts of cyclodextrins. In: Szejtli, J. (Ed.), Proceedings of the First International Symposium on Cyclodextrins, Budapest, Hungary, 30 September-2 October 1981. Cyclolab, Cyclodextrin Research and Development Laboratory Ltd., Budapest, Hungary.